希罗达治疗中晚期肝癌的临床研究

目的:国内外推荐希罗达为晚期或复发转移性结直肠癌和复发转移性乳腺癌一线用药。本研究探讨希罗达在中晚期肝癌中的临床应用。方法:中晚期肝癌患者随机分为两组,治疗组:15例服用希罗达每日1500mg/m2,分2次口服,服用14d,停药7d,每21天为一个疗程,至少服用2个疗程以上。对照组:16例采用积极的对症支持治疗。结果:治疗组和对照组的总有效率分别为13.3%、0;临床获益率为53.3%、0;肿瘤缩小率为40.0%、0;甲胎蛋白(AFP)下降率为45.5%、12.5%;中位生存期为9.6月、4.7月,P均<0.05。服用希罗达主要不良反应为手足综合征、腹泻、骨髓抑制及转氨酶增高。结论:希罗达治疗中晚期肝癌安全、有效,优于支持治疗。

Study on capecitabine for advanced liver cancer

Objective:Capecitabine is currently used as first-line therapy in patients with advanced or metastatic colorectal cancer or breast cancer.The abjectie of this study is to evaluate the clinical efficacy of capecitabine for advanced liver cancer. Methods: Patients with liver cancer were randomly divided into two groups. In the treatment group, 15 patients received oral capecitabine at 750 mg/ m~2, twice-daily for 14 days followed by 7-day rest period and repeated in three-week intervals. Every patient received at least two periods. In the control group, 16 patients received only supporting therapy. Results: In the treatment group and the control group: the overall response rates were 13.3 and 0.0 respectively; the benefit rates were 53.3 and 0.0; The tumor reduction rates were 40.0 and 0.0 respectively; The AFP reduction rates were 45.5 and 12.5 respectively; The median survival times were 9.6 months and 4.7 months respectively (All P<0.05). The most common side-effects of capecitabine were hand-foot syndrome, diarrhea, myelosuppression and hypohepatia. Conclusion: Capecitabine is safe and effective for advanced liver cancer and more superior than supporting therapy.